Martin Dreyling and Michael E. Williams (eds.)Hematologic MalignanciesRare Lymphomas201410.1007/978-3-642-39590-1_4 © Springer-Verlag Berlin Heidelberg 2014 4. Signaling Pathways in Rare Lymphomas Andrew Lipsky1, Patricia Pérez-Galán3, Claudio Agostinelli4, Pier Paolo Piccaluga4, Stefano A. Pileri4 and Adrian Wiestner2 (1) Department of Internal Medicine, Montefiore Medical Center,…
Author (year) n PFS OS SMZL Thieblemont et al. (2002) 81 Presence of M-component Beta2 microglobulin ≥3 mg/L Presence of animmunological event Leukocytes ≥20 109/L Lymphocytosis ≥9 109/L Presence of…
Fig. 6.1 (a and b) ALCL, ALK- with large tumor cells containing pleomorphic nuclei 6.3 Immunophenotype The tumor cells of ALCL, ALK-positive and ALK-negative, universally express CD30 and a majority…
Mature leukemias • T-cell prolymphocytic leukemia • T-cell large granular lymphocytic leukemia • Chronic lymphoproliferative disorders of NK-cells • Aggressive NK-cell leukemia • Adult T-cell leukemia/lymphoma • Sezary syndrome Mature…
Fig. 1 A Performance of the Lymph2Cx assay using an abbreviated gene set (20 genes) compared to the “gold standard method” of previously reported GEP as well as three IHC-based algorithms…
Prognostic group # risk factorsa Low risk 0, 1 Low intermediate 2 High intermediate 3 High 4, 5 aelevated LDH, advanced stage (Ann Arbor III/IV), age > 60, ≥ 2 extralymphatic sites of involvement…
Fig. 1 a Kaplan–Meier curve showing progressive improvement in the overall survival of FL patients over time. b Patients diagnosed and treated in post-rituximab era-2 (light color) had a statistically significant…
Fig. 1 Incidence Rates of NHL subtypes in the USA, 2000–2011, Surveillance, Epidemiology, and End-Results Program (Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat), Version 8.1.5. Surveillance, Epidemiology, and End…
IgM monoclonal gammopathy of any concentration Bone marrow infiltration by small lymphocytes showing plasmacytic differentiation Intertrabecular pattern of bone marrow infiltration Surface IgM+, CD19+, CD20+, CD22+, CD25+. CD27+, FMC7+, CD5±,…
1 No uptake 2 Uptake ≤ mediastinum 3 Uptake > mediastinum but ≤ liver 4 Uptake moderately higher than liver 5 Uptake markedly higher than liver and/or new lesions X New areas of uptake unlikely to…
